Cancer-associated Thrombosis – CAT.

Abstract

Patients with active cancer have a heightened risk for venous thromboembolism, which is a leading cause for increased morbidity and mortality for in-hospital as well as for ambulatory patients. With clinical risk prediction models, as for example the Khorana Score, it is of utmost interest to identify patients who are at the highest risk to develop a cancer-associated thrombosis. As this complication is increasing in prevalence and data is now available on the efficacy and safety of direct oral anticoagulants for the therapy of cancer-associated thrombosis, more research is needed to keep pace in this heterogeneous and complex group of patients. Deeper understanding of anticoagulant options will allow clinicians to individualize management and enhance patient quality of care.